Alachua, Florida

Overall Rank: 44
Category: Biotechnology
Category Rank: 20


Axogen’s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Avive+ Soft Tissue Matrix TM, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM.

Key Products

Solutions for your clinical needs

Axogen takes pride in pioneering regenerative medicine solutions and being the only company solely dedicated to peripheral nerve repair. Their comprehensive suite of clinically proven solutions for nerve repair needs ranges from injured nerves in continuity, to deficits up to 70 mm, and non-reconstructable nerve ends.

Repair transected nerves

Axogen believes that repairing transected nerves is critical for the return of sensation and motor function. Learn more about their solutions for reconstructing peripheral nerve discontinuities.

Protect damaged nerves

Axogen believes that protecting damaged nerves during the healing process is important for more consistent patient outcomes. Learn how their solutions help minimize neuroma formation and protect nerves from soft tissue attachments and mechanical stimulation.

Assess nerve damage

Axogen believes that assessing nerve damage and evaluating nerve regeneration is an important aspect of patient care.

To know more, click here.

Key Executives

  • Karen Zaderej, Chairman, Chief Executive Officer, and President

  • Marc Began, Executive Vice President and General Counsel

  • Nir Naor, Chief Financial Officer

  • Erick DeVinney, Chief Innovation Officer

  • Jens Schroeder Kemp, Chief Marketing Officer

  • Ivica Ducic, Chief Medical Officer

  • Todd Puckett, Vice President of Operations

  • Stacy Arnold, Vice President of Product Development and Clinical Research

  • Al Jacks, Vice President of Quality

  • Angela Nelson, Vice President of Regulatory Affairs

  • Doris Quackenbush, Vice President of Sales

To view their executive page, click here.

News and Press Releases

  • May 2024: Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® (Read).

  • May 2024: Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (Read).

  • May 2024: Axogen, Inc Reports First Quarter 2024 Financial Results (Read).

To view their full press release, click here.

Corporate Responsibility

Responsible Procurement Practices

Axogen values maintaining their legacy of integrity and the role we play as stewards of fair working conditions, basic human rights, and procuring the safest components for our products. Accordingly, they focus on educating their employees, suppliers, and business partners on their expectations as we engage in commerce.